Sourced from Pear Therapeutics
BOSTON and SAN FRANCISCO, June 18, 2020 — Pear Therapeutics, Inc. today announced that the Health Science Authority (HSA) of Singapore has authorized reSET® for the treatment of adults with substance use disorder (SUD) in that country. This is the first time the HSA has authorized a prescription digital therapeutic (PDT) with claims to treat disease and/or improve clinical outcomes in a disease.
“HSA market authorization reflects our mission to deliver our PDTs worldwide. This first authorization of a PDT outside the U.S. represents an important milestone for Pear and builds on the embrace of PDTs for the treatment of serious diseases like substance use disorder. We look forward to expansion of PDTs to Asia, beginning with providing patients and providers access to reSET in Singapore,” said Corey McCann, M.D., Ph.D., President and CEO of Pear.
reSET, a 12-week (90-day) prescription treatment to be used in conjunction with outpatient clinician-delivered care, will be distributed by local partners to eligible patients in Singapore. reSET offers interactive treatment modules that deliver cognitive behavioral therapy, fluency training to reinforce proficiency, and contingency management. Within a clinician dashboard, clinicians can follow patient-reported substance use, cravings, and triggers to facilitate transparency and encourage deeper interaction between patients and clinicians at face-to-face meetings.
Read more here.